Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP

Detalhes bibliográficos
Autor(a) principal: Costa Clemens, Sue Ann
Data de Publicação: 2022
Outros Autores: Fortaleza, Carlos Magno Castelo Branco [UNESP], Crowe, Madeleine, Tasca, Karen Ingrid [UNESP], Spadaro, André Gasparini, Souza-Neto, Jayme Augusto [UNESP], Grotto, Rejane Maria Tommasini [UNESP], Sider, Regina, Jimeno, Jose, Verstraeten, Thomas, Clemens, Ralf
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3389/fpubh.2022.1016402
http://hdl.handle.net/11449/246184
Resumo: Introduction: As the COVID-19 pandemic progresses, rapidly emerging variants of concern raise fears that currently licensed vaccines may have reduced effectiveness against these new strains. In the municipality of Botucatu, São Paulo State, Brazil, a mass vaccination campaign using ChadOx1-nCoV19 was initiated on 16th of May 2021, targeting people 18–60 years old. Two vaccine doses were offered 12 weeks apart, with the second delivered on 8th of August, 2021. This setting offered a unique opportunity to assess the effectiveness of two ChadOx1-nCoV19 doses in a real-life setting. Materials and methods: Data on testing, hospitalization, symptoms, demographics, and vaccination were obtained from the Hospital das Clínicas da Faculdade de Medicina de Botucatu. A test-negative study design was employed; whereby the odds of being vaccinated among cases vs controls were calculated to estimate vaccine effectiveness (VE; 1-OR). All individuals aged 18–60 who received a PCR test after the 16th of May and were unvaccinated prior to this date were included in the analysis until the study ended in mid-November 2021. Results: 77,683 citizens of Botucatu aged 18–60 received the first dose, and 74,051 received a second ChadOx1-nCoV19 dose 12 weeks later for a vaccination coverage of 84.2 and 80.2%, respectively. Of 7.958 eligible PCR tests, 2.109 were positive and 5.849 negative. The VE against any symptomatic infection was estimated at 39.2%, 21 days after dose 1, and 74.5%, 14 days after dose 2. There were no COVID-19-related hospitalizations or deaths among the 74,051 fully vaccinated individuals. The VE against severe disease was estimated at 70.8 and 100% after doses 1 and 2, respectively. 90.5% of all lineages sequenced between doses 1 and 2 (16th of May−7th of August) were of the Gamma variant, while 83.0% were of the Delta variant during the second period after dose 2 (8th of August−18th of November). Discussion: This observational study found the effectiveness of ChadOx1-nCoV19 to be 74.5% against COVID-19 disease of any severity, comparable to the efficacy observed in clinical trials (81.3% after dose 2), despite the dominance of the Gamma and Delta VoCs. No COVID-19-related hospitalizations or deaths in fully vaccinated individuals were reported.
id UNSP_c00783dc575faa042f8db5b4ddbee03d
oai_identifier_str oai:repositorio.unesp.br:11449/246184
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SPChadOx1COVID-19effectivenessvaccinesvariants of concern“real world” studyIntroduction: As the COVID-19 pandemic progresses, rapidly emerging variants of concern raise fears that currently licensed vaccines may have reduced effectiveness against these new strains. In the municipality of Botucatu, São Paulo State, Brazil, a mass vaccination campaign using ChadOx1-nCoV19 was initiated on 16th of May 2021, targeting people 18–60 years old. Two vaccine doses were offered 12 weeks apart, with the second delivered on 8th of August, 2021. This setting offered a unique opportunity to assess the effectiveness of two ChadOx1-nCoV19 doses in a real-life setting. Materials and methods: Data on testing, hospitalization, symptoms, demographics, and vaccination were obtained from the Hospital das Clínicas da Faculdade de Medicina de Botucatu. A test-negative study design was employed; whereby the odds of being vaccinated among cases vs controls were calculated to estimate vaccine effectiveness (VE; 1-OR). All individuals aged 18–60 who received a PCR test after the 16th of May and were unvaccinated prior to this date were included in the analysis until the study ended in mid-November 2021. Results: 77,683 citizens of Botucatu aged 18–60 received the first dose, and 74,051 received a second ChadOx1-nCoV19 dose 12 weeks later for a vaccination coverage of 84.2 and 80.2%, respectively. Of 7.958 eligible PCR tests, 2.109 were positive and 5.849 negative. The VE against any symptomatic infection was estimated at 39.2%, 21 days after dose 1, and 74.5%, 14 days after dose 2. There were no COVID-19-related hospitalizations or deaths among the 74,051 fully vaccinated individuals. The VE against severe disease was estimated at 70.8 and 100% after doses 1 and 2, respectively. 90.5% of all lineages sequenced between doses 1 and 2 (16th of May−7th of August) were of the Gamma variant, while 83.0% were of the Delta variant during the second period after dose 2 (8th of August−18th of November). Discussion: This observational study found the effectiveness of ChadOx1-nCoV19 to be 74.5% against COVID-19 disease of any severity, comparable to the efficacy observed in clinical trials (81.3% after dose 2), despite the dominance of the Gamma and Delta VoCs. No COVID-19-related hospitalizations or deaths in fully vaccinated individuals were reported.Department of Pediatrics Oxford UniversityMedical School Institute for Global Health Siena UniversityDepartment of Infectious Diseases Botucatu Medical School São Paulo State University (Universidade Estadual Paulista), São Paulo StateP95 Epidemiology & PharmacovigilanceBotucatu Health Department, São Paulo StateDepartment of Biotechnology Faculty of Agronomical Sciences São Paulo State University (Universidade Estadual Paulista), São Paulo StateDepartment of Clinical Medicine Botucatu Medical School São Paulo State University (Universidade Estadual Paulista), São Paulo StateIntrialsVaxtrialsInternational Vaccine Institute (IVI)Department of Infectious Diseases Botucatu Medical School São Paulo State University (Universidade Estadual Paulista), São Paulo StateDepartment of Biotechnology Faculty of Agronomical Sciences São Paulo State University (Universidade Estadual Paulista), São Paulo StateDepartment of Clinical Medicine Botucatu Medical School São Paulo State University (Universidade Estadual Paulista), São Paulo StateOxford UniversitySiena UniversityUniversidade Estadual Paulista (UNESP)P95 Epidemiology & PharmacovigilanceBotucatu Health DepartmentIntrialsVaxtrialsInternational Vaccine Institute (IVI)Costa Clemens, Sue AnnFortaleza, Carlos Magno Castelo Branco [UNESP]Crowe, MadeleineTasca, Karen Ingrid [UNESP]Spadaro, André GaspariniSouza-Neto, Jayme Augusto [UNESP]Grotto, Rejane Maria Tommasini [UNESP]Sider, ReginaJimeno, JoseVerstraeten, ThomasClemens, Ralf2023-07-29T12:34:01Z2023-07-29T12:34:01Z2022-10-13info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fpubh.2022.1016402Frontiers in Public Health, v. 10.2296-2565http://hdl.handle.net/11449/24618410.3389/fpubh.2022.10164022-s2.0-85140848369Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengFrontiers in Public Healthinfo:eu-repo/semantics/openAccess2023-07-29T12:34:01Zoai:repositorio.unesp.br:11449/246184Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462023-07-29T12:34:01Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
title Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
spellingShingle Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
Costa Clemens, Sue Ann
ChadOx1
COVID-19
effectiveness
vaccines
variants of concern
“real world” study
title_short Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
title_full Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
title_fullStr Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
title_full_unstemmed Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
title_sort Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
author Costa Clemens, Sue Ann
author_facet Costa Clemens, Sue Ann
Fortaleza, Carlos Magno Castelo Branco [UNESP]
Crowe, Madeleine
Tasca, Karen Ingrid [UNESP]
Spadaro, André Gasparini
Souza-Neto, Jayme Augusto [UNESP]
Grotto, Rejane Maria Tommasini [UNESP]
Sider, Regina
Jimeno, Jose
Verstraeten, Thomas
Clemens, Ralf
author_role author
author2 Fortaleza, Carlos Magno Castelo Branco [UNESP]
Crowe, Madeleine
Tasca, Karen Ingrid [UNESP]
Spadaro, André Gasparini
Souza-Neto, Jayme Augusto [UNESP]
Grotto, Rejane Maria Tommasini [UNESP]
Sider, Regina
Jimeno, Jose
Verstraeten, Thomas
Clemens, Ralf
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Oxford University
Siena University
Universidade Estadual Paulista (UNESP)
P95 Epidemiology & Pharmacovigilance
Botucatu Health Department
Intrials
Vaxtrials
International Vaccine Institute (IVI)
dc.contributor.author.fl_str_mv Costa Clemens, Sue Ann
Fortaleza, Carlos Magno Castelo Branco [UNESP]
Crowe, Madeleine
Tasca, Karen Ingrid [UNESP]
Spadaro, André Gasparini
Souza-Neto, Jayme Augusto [UNESP]
Grotto, Rejane Maria Tommasini [UNESP]
Sider, Regina
Jimeno, Jose
Verstraeten, Thomas
Clemens, Ralf
dc.subject.por.fl_str_mv ChadOx1
COVID-19
effectiveness
vaccines
variants of concern
“real world” study
topic ChadOx1
COVID-19
effectiveness
vaccines
variants of concern
“real world” study
description Introduction: As the COVID-19 pandemic progresses, rapidly emerging variants of concern raise fears that currently licensed vaccines may have reduced effectiveness against these new strains. In the municipality of Botucatu, São Paulo State, Brazil, a mass vaccination campaign using ChadOx1-nCoV19 was initiated on 16th of May 2021, targeting people 18–60 years old. Two vaccine doses were offered 12 weeks apart, with the second delivered on 8th of August, 2021. This setting offered a unique opportunity to assess the effectiveness of two ChadOx1-nCoV19 doses in a real-life setting. Materials and methods: Data on testing, hospitalization, symptoms, demographics, and vaccination were obtained from the Hospital das Clínicas da Faculdade de Medicina de Botucatu. A test-negative study design was employed; whereby the odds of being vaccinated among cases vs controls were calculated to estimate vaccine effectiveness (VE; 1-OR). All individuals aged 18–60 who received a PCR test after the 16th of May and were unvaccinated prior to this date were included in the analysis until the study ended in mid-November 2021. Results: 77,683 citizens of Botucatu aged 18–60 received the first dose, and 74,051 received a second ChadOx1-nCoV19 dose 12 weeks later for a vaccination coverage of 84.2 and 80.2%, respectively. Of 7.958 eligible PCR tests, 2.109 were positive and 5.849 negative. The VE against any symptomatic infection was estimated at 39.2%, 21 days after dose 1, and 74.5%, 14 days after dose 2. There were no COVID-19-related hospitalizations or deaths among the 74,051 fully vaccinated individuals. The VE against severe disease was estimated at 70.8 and 100% after doses 1 and 2, respectively. 90.5% of all lineages sequenced between doses 1 and 2 (16th of May−7th of August) were of the Gamma variant, while 83.0% were of the Delta variant during the second period after dose 2 (8th of August−18th of November). Discussion: This observational study found the effectiveness of ChadOx1-nCoV19 to be 74.5% against COVID-19 disease of any severity, comparable to the efficacy observed in clinical trials (81.3% after dose 2), despite the dominance of the Gamma and Delta VoCs. No COVID-19-related hospitalizations or deaths in fully vaccinated individuals were reported.
publishDate 2022
dc.date.none.fl_str_mv 2022-10-13
2023-07-29T12:34:01Z
2023-07-29T12:34:01Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3389/fpubh.2022.1016402
Frontiers in Public Health, v. 10.
2296-2565
http://hdl.handle.net/11449/246184
10.3389/fpubh.2022.1016402
2-s2.0-85140848369
url http://dx.doi.org/10.3389/fpubh.2022.1016402
http://hdl.handle.net/11449/246184
identifier_str_mv Frontiers in Public Health, v. 10.
2296-2565
10.3389/fpubh.2022.1016402
2-s2.0-85140848369
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Frontiers in Public Health
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799965272478580736